In vitro activity of lefamulin against sexually transmitted bacterial pathogens [PublishAheadOfPrint]

The pleuromutilin antibiotic lefamulin demonstrated in vitro activity against the most relevant bacterial pathogens causing sexually transmitted infections (STI) including Chlamydia trachomatis (MIC_50/90 of 0.02/0.04 mg/L, n=15), susceptible and multidrug-resistant Mycoplasma genitalium (MIC range 0.002-0.063 mg/L, n=6) and susceptible and resistant Neisseria gonorrhoeae (MIC_50/90, 0.12/0.5 mg/L, n=25). The results suggest that lefamulin could be a promising first-line antibiotic for the treatment of STI, particularly in populations with high resistance rates to standard of care antibiotics.

http://ift.tt/2Hv9Fsn